Company swings to profitability with $54.4M adjusted EBITDA and raises full-year guidance.

Moby summary of P3 Health Partners Inc.'s Q2 2026 earnings call

P3 Health Partners (NASDAQ:PIII) reported second-quarter adjusted EBITDA of $54 million and raised its full-year 2026 outlook, while noting that the quarterly result included $45 million of favorable payer settlements and prior-year development. Chief Executive Officer Aric Coffman said the company

P3 Health Partners' (PIII) shares soared 182% amid heavy trading after the company posted overnight

Moby summary of P3 Health Partners Inc.'s Q1 2026 earnings call

P3 Health Partners Inc (PIII) reports robust Q1 performance, raises full-year outlook, and enhances balance sheet through strategic debt conversion.

The recent move to a reduced US$12.50 price target for P3 Health Partners, alongside an unchanged fair value estimate of US$10.25, signals a recalibration of expectations rather than a rewrite of the core story. Bullish analysts see the updated target as a reset on timing after weaker Q3 aEBITDA, while still pointing to underlying operational progress that they believe is not fully showing up in the numbers yet. As you read on, keep an eye on how these differing views shape the evolving...

P3 Health Partners has seen its price target revised to $12.50 even as fair value per share holds steady at $10.25 and the discount rate remains fixed at 12.5%. This underscores a more nuanced narrative around risk and long term potential. While analysts wrestle with a Q3 aEBITDA miss and stronger revenue growth expectations of roughly 11.1% vs prior 6.1%, the updated target reflects a recalibration of timing rather than a complete rethink of the growth story. Read on to see how you can stay...

P3 Health Partners has seen its price target recalibrated, even as the core assumptions behind its fair value of $10.25 per share, the 12.5% discount rate, and roughly 6.1% revenue growth remain effectively intact. This tweak is being framed as a fine tuning of expectations around near term execution risk, not a reversal of confidence in the company’s long term earnings path. Read on to see how investors can stay ahead of these narrative shifts as new data points emerge. Analyst Price Targets...